论文部分内容阅读
目的观察琥珀酸美托洛尔联合厄贝沙坦治疗慢性充血性心力衰竭的临床疗效。方法 70例慢性充血性心力衰竭患者分为两组,治疗组予琥珀酸美托洛尔联合厄贝沙坦治疗,对照组以厄贝沙坦治疗为主,6个月后评价心功能分级和LVEF情况。结果治疗组心功能改善总有效率91.4%,明显高于对照组的65.7%(P<0.05),治疗组患者LVEF明显好于对照(P<0.05)。结论应用琥珀酸美托洛尔联合厄贝沙坦治疗慢性充血性心力衰竭疗效明显,值得推广。
Objective To observe the clinical efficacy of metoprolol succinate combined with irbesartan in the treatment of chronic congestive heart failure. Methods Seventy patients with chronic congestive heart failure were divided into two groups: the treatment group received metoprolol succinate combined with irbesartan, and the control group received irbesartan therapy. After 6 months, the patients were assessed for heart function classification and LVEF situation. Results The total effective rate of improvement of cardiac function in the treatment group was 91.4%, which was significantly higher than that in the control group (65.7%, P <0.05). The LVEF in the treatment group was significantly better than that in the control group (P <0.05). Conclusion Metoprolol succinate combined with irbesartan in the treatment of chronic congestive heart failure obvious effect, it is worth promoting.